Equity Overview
Price & Market Data
Price: $26.11
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $244,413,104
Volume: 0
Performance Metrics
1 Week: 6.57%
1 Month: -1.62%
3 Months: 70.32%
6 Months: 172.7%
1 Year: 16.19%
YTD: 42.21%
Company Details
Employees: 10
Sector: Health technology
Industry: Biotechnology
Country:
Details
Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Sugar Land, Texas.